{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-110019","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.357128+00:00","generated_at":"2026-05-23T01:10:33.109345+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AN2 Therapeutics Phase 3 EBO-301 misses primary endpoint; outlines boron pipeline milestones, cash runway into 2028","bullets":["Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.","Cash, cash equivalents & investments $78.5M as of March 31, 2025; cash runway extended into 2028.","Initiated start up for Phase 1 study of AN2-502998 for chronic Chagas disease, expected completion in 2H25.","Plans Phase 2 study for epetraborole in melioidosis in 2H25 aiming to reduce ~40% mortality.","First oncology compounds from boron platform on track for development in 2H25, targeting ENPP1, PI3Kα."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-110019","json":"https://secwatch.observer/filing/0001193125-25-110019.json","markdown":"https://secwatch.observer/filing/0001193125-25-110019.md","text":"https://secwatch.observer/filing/0001193125-25-110019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/0001193125-25-110019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/d116214d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:10:33.109345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}